Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd lifted its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 101.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,616 shares of the company’s stock after acquiring an additional 24,951 shares during the period. XTX Topco Ltd’s holdings in Atossa Therapeutics were worth $75,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ATOS. Bank of New York Mellon Corp lifted its position in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after purchasing an additional 399,041 shares during the period. Rhumbline Advisers bought a new stake in shares of Atossa Therapeutics in the 2nd quarter worth $161,000. Renaissance Technologies LLC lifted its holdings in shares of Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after buying an additional 164,540 shares during the period. SG Americas Securities LLC boosted its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after buying an additional 30,037 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Atossa Therapeutics in the third quarter worth about $29,000. 12.74% of the stock is currently owned by institutional investors.

Atossa Therapeutics Trading Down 1.7 %

NASDAQ ATOS opened at $0.96 on Friday. Atossa Therapeutics, Inc. has a 1 year low of $0.72 and a 1 year high of $2.31. The company has a market cap of $121.23 million, a PE ratio of -4.38 and a beta of 1.21. The stock’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.32.

Wall Street Analyst Weigh In

ATOS has been the subject of several research reports. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research report on Thursday, December 12th.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.